NSPR
InspireMD, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
2.05
P/S
8.03
EV/EBITDA
-1.34
DCF Value
$-4.52
FCF Yield
-51.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
29.5%
Operating Margin
-552.6%
Net Margin
-543.3%
ROE
-116.2%
ROA
-70.3%
ROIC
-84.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $3.1M | $-11.8M | $-0.14 |
| FY 2025 | $9.0M | $-48.8M | $-0.76 |
| Q3 2025 | $2.5M | $-12.7M | $-0.17 |
| Q2 2025 | $1.8M | $-13.2M | $-0.26 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
IL
Exchange
NASDAQ
Beta
0.94
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.